Table S13: Enrichment of binding sites for NF-kB and p53 in chromatin regions that become accessible or closed, respectively, upon TONSL overexpression. Genes names and chromatin positions are indicated.

Table S2: Gene expression differences between mature luminal and luminal progenitor cells of the breast. Data are from 15 samples, five each from women of European, African and Latina ancestry.

Contains additional materials and methods and supplementary figures

Table S8: Multivariable analysis for overall (N=469) and progression-free (N=453) survival NOT including HER2. Overall and Progression-Free survival data of patients with ER+ breast cancer and treated with endocrine therapy are also shown.

Table S1: Gene expression differences between primary and hTERT-immortalized breast epithelial cell lines.

Table S15: List of genes differentially expressed upon TONSL overexpression in primary cells with genes differentially expressed in TMD-436 upon TONSL knockdown. Fold changes in gene expression are indicated.

Table S5: Description of the patients and characteristics of their tumors (n=597)

Table S11: The effects of TONSL overexpression on proliferation signature of breast tumors.

Table S9: Results of ATAC-seq of primary and TONSL-immortalized cells.

Table S14: Genes differentially expressed in TMD-436pLKO and TMD-436shTONSL cells. Fold changes in gene expression are indicated.

Table S10: Results of RNA-seq analysis of primary and TONSL-immortalized cells. Fold differences in expression are shown.

Table S12: List of interactors and antagonists of BRCA1-BRAD1 complex. Fold changes in gene expression are indicated.

Table S4: Breast cancers with TONSL amplification selectively overexpress genes associated with E2F targets, G2/M checkpoint, mitotic spindle and mTORC1 pathways.

Table S3: DepMap analysis reveals gene essentiality for survival of select genes upregulated in immortalized cells compared to primary cells.

Table S7: Univariable analysis of other tumor markers for overall and progression-free survival

Table S6: Bivariate analysis of TONSL H-score with other tumor markers

PathView normalized signature scores for biological pathways relevant to tumor progression, immune response and tumor microenvironment for each sample.

Normalized count matrix. Probes with raw counts below threshold were excluded.

Raw count matrix and probe annotations.

Supplemental Figure 10. Survivin inhibition with LQZ-7I abrogates viability of human MPNST and murine primary Schwann cell precursors.